The European Medicines Agency recommended approval of two generic organ rejection drugs manufactured by Teva Pharmaceutical Industries Ltd. The two medicines, which are generic versions of Roche Holding's CellCept, are indicated for the prevention of acute transplant rejection in kidney, heart or liver transplant patients.

Full Story:
Globes (Israel)

Related Summaries